Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Sprout Health vs This Gen Wellness

Two GLP-1 desks, one scoreboard. We put Sprout Health and This Gen Wellness head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 6 · Grade B

Sprout Health

Visit Sprout Health Full brief →
vs
No. 428 · Grade C

This Gen Wellness

Visit This Gen Wellness Full brief →

The verdict

Sprout Health takes this head-to-head.

Sprout Health scores 86 to 53 on our six-factor Brief Score — A LegitScript-certified desk that pairs low-cost compounded semaglutide and tirzepatide with a real brand-name Wegovy and Zepbound path — and a near-frictionless, often visit-free start.

That doesn't make This Gen Wellness a bad call — it's best for readers who want new yorkers who want a required live video visit rather than a form-only intake. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
90
28
Supply Reliability
82
84
Transparency
88
29
Access Breadth
92
36
Clinical Oversight
78
80
Track Record
84
75
Sprout HealthBrief Score 86 · 53This Gen Wellness

Price, coverage & the tracker

Sprout HealthThis Gen Wellness
Brief Score86/100 (B)53/100 (C)
Semaglutide$149/moNot disclosed
Tirzepatide$199/moNot disclosed
CoverageNot disclosed1 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Sprout Health: Compounded $149 semaglutide / $199 tirzepatide held flat this cycle, with a brand-name Wegovy/Zepbound path available on the same account.

This Gen Wellness: New to the tracker on 1 August 2026. This program publishes no monthly medication price, so there is no line for us to track until it does.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.